Section: Pet Parasites

Feline Toxoplasmosis: Zoonotic Potential and Human Health Implications

1. Introduction

Toxoplasma gondii is a globally distributed obligate intracellular apicomplexan parasite that infects virtually all warm‑blooded vertebrates [1, 2]. Felids, including domestic cats (Felis catus), serve as the only definitive hosts and are central to the parasite’s epidemiology because they alone shed environmentally resistant oocysts in their feces [1, 3, 2]. Feline toxoplasmosis therefore represents a critical interface for zoonotic transmission, and understanding its biology, diagnosis, and control is essential for public health [1, 4, 5]. This review integrates current knowledge on the zoonotic potential of T. gondii from cats to humans, with emphasis on parasite life‑cycle stages, transmission routes, clinical presentations in humans, diagnostic methodologies, treatment options, and preventive measures.

2. Life Cycle of Toxoplasma gondii

The life cycle of T. gondii involves both sexual replication in the feline definitive host and asexual replication in intermediate hosts (including humans) [1, 2]. Cats become infected by ingesting tissue cysts containing bradyzoites from infected prey (e.g., rodents, birds) or, less commonly, by ingesting sporulated oocysts from contaminated environments [6, 7]. After ingestion, bradyzoites or sporozoites invade intestinal epithelial cells and undergo multiple rounds of schizogony (asexual multiplication), followed by gametogony and fertilization, leading to the production of unsporulated oocysts that are shed in feces [1, 8, 2]. Shedding typically begins 3–10 days after primary infection and may last 1–3 weeks, during which millions of oocysts can be excreted [1, 6]. These oocysts sporulate (become infectious) within 1–5 days in the environment, depending on temperature, humidity, and aeration, and can remain viable for months to years in soil, water, or on surfaces [2, 5].

Extraintestinal dissemination in both definitive and intermediate hosts occurs when tachyzoites (the rapidly dividing stage) disseminate via the bloodstream and lymphatics to various tissues, where they convert to bradyzoites and form tissue cysts, particularly in neural and muscular tissues [1, 9, 5]. In cats, intestinal stages (schizonts and gamonts) are central to oocyst production, and stage‑specific antigens expressed during schizogony and gametogony are targets for emerging diagnostic tools [1, 8].

3. Transmission from Cats to Humans

3.1. Oocyst‑Mediated Transmission

The primary route of zoonotic transmission is the accidental ingestion of sporulated oocysts shed by cats [3, 2, 10]. Oocysts can contaminate soil, gardening areas, children’s sandboxes, fruits and vegetables, and water sources [2, 5]. Humans become infected by:

  • Ingesting contaminated, unwashed produce [2].
  • Drinking untreated water containing oocysts [2].
  • Inhaling or ingesting dust from contaminated litter boxes or gardening soil [5].
  • Handling cat feces without proper hygiene (e.g., during litter‑box cleaning) [10].

3.2. Tissue Cyst‑Mediated Transmission

Humans also acquire infection by consuming undercooked or raw meat (especially pork, lamb, and game) that contains tissue cysts [2, 5]. This route does not directly involve cats, but cats contribute to environmental contamination with oocysts that can infect livestock [2]. Direct cat‑to‑human transmission through tissue cysts is not relevant, but the cat’s role in perpetuating the sylvatic cycle underscores its zoonotic importance.

3.3. Vertical (Congenital) Transmission and Other Routes

Congenital toxoplasmosis occurs when a woman acquires primary T. gondii infection during pregnancy, leading to transplacental passage of tachyzoites to the fetus [2]. While this does not involve direct cat contact, a cat‑contaminated environment is a potential source of the primary infection [2, 5]. Blood transfusion and organ transplantation are rare but documented routes in immunocompromised individuals [5].

4. Cat Toxoplasmosis Symptoms in Humans

The clinical spectrum of human toxoplasmosis varies from asymptomatic infection to severe disease, depending on host immune status and the stage of infection [2, 5]. The term cat toxoplasmosis symptoms in humans often refers to the manifestations of acute or reactivated infection acquired from feline sources.

4.1. Immunocompetent Individuals

In immunocompetent adults, primary infection is typically asymptomatic or causes a mild, self‑limiting illness [2, 5]. When symptoms occur, they may include:

  • Cervical or generalized lymphadenopathy (most common) [2].
  • Fever, malaise, night sweats, and myalgia [2].
  • Headache and sore throat [2].
  • Rarely, chorioretinitis (ocular toxoplasmosis) in the acute phase or after reactivation [11].

These clinical signs are non‑specific and may mimic viral syndromes or other infectious diseases, making laboratory confirmation essential [1, 2].

4.2. Immunocompromised Individuals

In individuals with suppressed cell‑mediated immunity (e.g., due to HIV/AIDS, organ transplantation, immunosuppressive therapy), latent infection can reactivate, leading to life‑threatening disease [12, 13, 14, 15]. The most common manifestation is cerebral toxoplasmosis, presenting with headache, confusion, seizures, and focal neurological deficits due to multiple ring‑enhancing brain lesions [2, 5]. Ocular toxoplasmosis (retinochoroiditis) may also occur or worsen [11]. Disseminated toxoplasmosis, involving the lungs, heart, and other organs, is frequently fatal [12, 13].

4.3. Congenital Toxoplasmosis

When a pregnant woman acquires primary infection, the fetus may develop congenital toxoplasmosis [2]. Clinical outcomes include:

  • Asymptomatic infection at birth (most cases).
  • Chorioretinitis, hydrocephalus, intracranial calcifications (classic triad) [2].
  • Neurological sequelae: seizures, developmental delay, intellectual disability.
  • Spontaneous abortion or stillbirth in severe cases [2].

5. Diagnosis of Zoonotic Infection

5.1. Serological Diagnosis in Humans

Detection of anti‑T. gondii IgG and IgM antibodies is the standard for diagnosing human infection [1, 16]. IgG seroconversion or a four‑fold rise in IgG titer indicates acute infection; the presence of IgM suggests recent acquisition but can persist for months [2]. In immunocompromised patients, serology may be unreliable, and direct detection methods are needed [5].

5.2. Molecular and Direct Detection

Polymerase chain reaction (PCR) for T. gondii DNA in blood, cerebrospinal fluid, amniotic fluid, or tissue biopsies provides definitive diagnosis, especially in congenital and cerebral toxoplasmosis [1, 5]. PCR is highly sensitive and can detect active infection [1].

5.3. Diagnostic Challenges in the Human‑Cat Interface

The diagnostic performance of serological tests for feline toxoplasmosis directly influences public health surveillance [1, 16, 17]. In cats, seroprevalence studies using immunochromatographic assays, ELISA, and latex agglutination tests indicate variable exposure rates (e.g., 21.8% in Greece, 60% for IgG in Kuwait) [18, 3]. Advanced recombinant‑antigen ELISAs (e.g., using SAG2, GRA2, GRA6, GRA7, GRA15, MIC10) have shown high concordance with traditional whole‑lysate assays and offer safer, standardizable alternatives for mass screening [16]. Emerging technologies, including microarray‑based multiplex serology and nanomaterial‑enhanced biosensors, are being developed to improve stage‑specific detection of oocyst shedding [1].

6. Treatment of Zoonotic Toxoplasmosis

6.1. Human Treatment Regimens

Standard therapy for acute toxoplasmosis in immunocompetent adults is generally not required unless symptoms are severe or persistent [2]. For ocular, congenital, or disseminated disease, the combination of pyrimethamine and sulfadiazine with folinic acid is the cornerstone of treatment [2, 5]. Alternative regimens include clindamycin plus pyrimethamine (especially in ocular disease) and atovaquone [2].

In immunocompromised patients (e.g., those with HIV/AIDS), lifelong suppressive therapy may be needed to prevent reactivation [5]. Primary prophylaxis (trimethoprim‑sulfamethoxazole) is recommended for HIV‑positive patients with CD4 counts below 100 cells/μL and seropositive for T. gondii [2, 5].

6.2. Addressing the Feline Source

Treatment of infected cats can reduce oocyst shedding and lower environmental contamination [1, 13, 17]. The recommended protocol is clindamycin (10–12 mg/kg orally twice daily for 2–4 weeks) [19, 20, 13]. Azithromycin, doxycycline, and atovaquone are alternative options [4, 11]. However, treatment does not eliminate tissue cysts, and cats can be reinfected [4, 5]. Therefore, public health strategies emphasize prevention of feline infection rather than treatment of individual cats [17].

7. Prevention of Zoonotic Infection

Preventive measures target both the feline source and human exposure routes [3, 2, 17]. A logical framework is presented in the decision tree below.

flowchart TD
    A[Prevention of zoonotic toxoplasmosis], > B[Reduce oocyst contamination from cats]
    A, > C[Reduce human exposure to oocysts and tissue cysts]
    
    B, > D[Keep cats indoors to prevent hunting]
    B, > E[Feed cats only cooked or commercial food]
    B, > F[Prompt removal and disinfection of cat feces]
    B, > G[Litter box cleaning by immunocompetent, non-pregnant individuals]
    
    C, > H[Wash hands after contact with cat or soil]
    C, > I[Wash fruits and vegetables thoroughly]
    C, > J[Cook meat to safe internal temperatures]
    C, > K[Wear gloves when gardening]
    C, > L[Avoid untreated water sources]
    
    D, > M[Reduce risk of cat infection]
    E, > M
    F, > N[Prevent sporulation of oocysts]
    G, > N

7.1. Managing the Feline Reservoir

  • Keep cats indoors to prevent hunting and scavenging [3, 21, 5].
  • Feed cats only commercially processed or thoroughly cooked meat [2, 5].
  • Clean litter boxes daily (oocysts require >24 hours to sporulate) and dispose of feces in sealed bags [2, 17].
  • Pregnant women and immunocompromised individuals should avoid handling litter boxes; if unavoidable, wear disposable gloves and wash hands thoroughly [2, 5].

7.2. Reducing Human Exposure

  • Practice rigorous hand hygiene after contact with cats, soil, or raw meat [2].
  • Wash all fruits and vegetables before consumption [2].
  • Cook meat to at least 66°C (150°F) in the center or freeze at −20°C for several days to inactivate tissue cysts [2].
  • Use gloves while gardening and avoid touching the face [5].
  • Cover children’s sandboxes when not in use to prevent cat fecal contamination [2].

7.3. One Health Surveillance

Seroprevalence surveys in cats provide indirect estimates of environmental oocyst burden [18, 3, 22]. Integrating serological data from cats with human case reporting and environmental sampling (e.g., PCR‑based detection of oocysts in water and soil) strengthens one health surveillance [1, 3]. Risk factor analysis (e.g., outdoor access, hunting, feeding raw meat) identifies high‑risk populations for targeted education [3, 21, 23].

8. Conclusion

Feline toxoplasmosis remains a significant zoonotic concern due to the unique role of cats as definitive hosts of T. gondii. The parasite’s ability to persist in the environment as oocysts and in human tissues as bradyzoite cysts drives its widespread prevalence. Diagnosis has advanced from traditional serology to recombinant antigen‑based assays and molecular platforms, enabling more rapid and stage‑specific detection [1, 16]. Prevention strategies focused on managing the feline reservoir and reducing human exposure are effective when consistently applied [3, 2, 17]. A one health approach encompassing veterinary medicine, human healthcare, and environmental monitoring is essential for reducing the global burden of toxoplasmosis [1, 3].

References

[1] Dan Zhao, Yanzhen Liao, Hao Liu et al. Comprehensive diagnostic approaches to feline toxoplasmosis: Bridging traditional methods and emerging technologies. Virulence, 2025. https://www.semanticscholar.org/paper/2e757aa2ddd10827f80fab2653e009ad1d5e71da

[2] K. Bresciani, A. L. Galvão, A. L. D. Vasconcellos et al. EPIDEMIOLOGICAL ASPECTS OF FELINE TOXOPLASMOSIS. 2016. https://www.semanticscholar.org/paper/6b9f21d91d91295b742aef77632d2525479580ce

[3] G. Sioutas, I. Symeonidou, A. Gelasakis et al. Feline Toxoplasmosis in Greece: A Countrywide Seroprevalence Study and Associated Risk Factors. Pathogens, 2022. https://www.semanticscholar.org/paper/7a38aa6feab78b556c75fca605f426eadd8440c4

[4] S. Caney. Update on feline toxoplasmosis. 2021. https://www.semanticscholar.org/paper/04388a62c4aa2e740b6e424bd443e7a1366da8e9

[5] M. Lappin. Chapter 28. Feline Toxoplasmosis. 2008. https://www.semanticscholar.org/paper/0d5233dd99e8824d4e4e00369f97cc6b0491eefa

[6] J. P. Dubey, J. K. Frenkel. Feline toxoplasmosis from acutely infected mice and the development of Toxoplasma cysts. The Journal of Protozoology, 1976. https://www.semanticscholar.org/paper/8baf73ffc19ee8034b04927ed5eb249b3daa9e18

[7] Y. Omata, H. Oikawa, M. Kanda et al. Experimental feline toxoplasmosis: humoral immune responses of cats inoculated orally with Toxoplasma gondii cysts and oocysts. Nihon Juigaku Zasshi, 1990. https://www.semanticscholar.org/paper/b51652947e0dfa715c4d08df67cd76221708e926

[8] Özlem Günay-Esiyok, Ecem Su Koçkaya, Rana Yılmaz et al. The Potential of MIC17A both as an Entero-epithelial and Chronic Stage Marker for Detection of Feline Toxoplasmosis. Current Microbiology, 2026. https://www.semanticscholar.org/paper/170f603aa98f7dd6b215d4a83f5f76f844c9e861

[9] R. Hirth, S. W. Nielsen. Pathology of feline toxoplasmosis. Journal of Small Animal Practice, 1969. https://www.semanticscholar.org/paper/70ea7aed2b1cd57cf4238050c1395234eaa98dde

[10] MacKnight Kt, Robinson Hw. Epidemiologic studies on human and feline toxoplasmosis. 1992. https://www.semanticscholar.org/paper/1f00a302a974f5cfc4ddec180eb6d4e0e52698df

[11] K. M. Ali, A. M. Abu-Seida, M. Abuowarda. Feline ocular toxoplasmosis: seroprevalence, diagnosis and treatment outcome of 60 clinical cases. Polish Journal of Veterinary Sciences, 2021. https://www.semanticscholar.org/paper/0d19fc80bf1bde129d6b11a3e14b5e0b7dc7192c

[12] A. Moore, A. Burrows, R. Malik et al. Fatal disseminated toxoplasmosis in a feline immunodeficiency virus‐positive cat receiving oclacitinib for feline atopic skin syndrome. Veterinary Dermatology, 2022. https://www.semanticscholar.org/paper/c931267329077e9f22210c3439872dddff053542

[13] E. A. Okewole, M. O. Akpan. Clinical feline toxoplasmosis: parasitological, haematological and serological findings in retroviral infected and uninfected cats. 2002. https://www.semanticscholar.org/paper/2e27851bb71e0ccb0409282c54991b0237af3d91

[14] L. Zandonà, R. Brunetta, C. Zanardello et al. Cerebral toxoplasmosis in a cat with feline leukemia and feline infectious peritonitis viral infections. The Canadian Veterinary Journal, 2018. https://www.semanticscholar.org/paper/9b883ef30868dedf42a1c8dc0e77da44dfe0abb2

[15] Nataly Mamaliger. Clinical toxoplasmosis in an immunosuppressed feline patient. 2018. https://www.semanticscholar.org/paper/400bc30d565cb1c935d6b52f3fbb2b149c47a5ff *** Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.

[16] A. Abdelbaset, Hend Alhasan, Doaa Salman et al. Evaluation of recombinant antigens in combination and single formula for diagnosis of feline toxoplasmosis. Experimental Parasitology, 2017. https://www.semanticscholar.org/paper/1fd2239858e29ce336d8d273dd32e3c1ed51f467

[17] M. Svoboda, J. Konrád, V. Svobodová. [Diagnosis and prevention of feline toxoplasmosis]. Tierarztliche Praxis, 1988. https://www.semanticscholar.org/paper/0c47806d4447df5d683949639d6bc30766a7b03b

[18] S. M. Ibrahim, I. Mohamed, S. E. Suliman et al. Seroprevalence of Feline Toxoplasmosis in Kuwait State. International Journal of Current Microbiology and Applied Sciences, 2025. https://www.semanticscholar.org/paper/f05f6b05b012c996ed244740c03869e7e95c3f5e

[19] M. Lappin, C. Greene, S. Winston et al. Clinical Feline Toxoplasmosis. 1989. https://www.semanticscholar.org/paper/1ae2d5c4420cf0ff662e99d9964dc6c34a70036b

[20] M. Lappin, C. Greene, S. Winston et al. Clinical feline toxoplasmosis. Serologic diagnosis and therapeutic management of 15 cases. Journal of Veterinary Internal Medicine, 1989. https://www.semanticscholar.org/paper/188e9c7e48bcd3dd733c4dadbdd3bf4a2c1dbf

[21] A. Brennan. Risk factors in feline toxoplasmosis. 2018. https://www.semanticscholar.org/paper/f488897999e2e89707722c6d17b4288f318c47a5

[22] J. Teixeira, Jéssica S Oliveira, D. Almeida et al. Seroprevalence of feline toxoplasmosis in Teresina, Piauí, Brazil. 2016. https://www.semanticscholar.org/paper/b5a75e8076e477c63e0ad3cf290165adcea31440

[23] A. Munhoz, Samir Batista Hage, R. Cruz et al. Toxoplasmosis in cats in northeastern Brazil: Frequency, associated factors and coinfection with Neospora caninum, feline immunodeficiency virus and feline leukemia virus. Veterinary Parasitology: Regional Studies and Reports, 2017. https://www.semanticscholar.org/paper/7c8a2fdd2e9561c2569bc4e98397bbe347e630a2

[24] J. L. Faria, C. Couto, Sheron L Wierzynski et al. Feline Toxoplasmosis: Tumor Necrosis Factor, Nitric Oxide, and Free Radicals in Seropositive Cats. Journal of Parasitology, 2018. https://www.semanticscholar.org/paper/6949c8c0034df3c74f48a543ed58094bbdee2c85

[25] P. Jokelainen, O. Simola, E. Rantanen et al. Feline toxoplasmosis in Finland. Journal of Veterinary Diagnostic Investigation, 2012. https://www.semanticscholar.org/paper/6a4fbacb25ee047707fcc3cc04c3c600dc321216

[26] J. Dubey, J. K. Frenkel. Immunity to Feline Toxoplasmosis: Modification by Administration of Corticosteroids. Veterinary Pathology-Supplement, 1974. https://www.semanticscholar.org/paper/7d02cb1226cf6abea11de16a6dd851250bc20241

[27] J. Dubey. Feline toxoplasmosis and coccidiosis: a survey of domiciled and stray cats. Journal of the American Veterinary Medical Association, 1973. https://www.semanticscholar.org/paper/ccb8d11ca9bbfc79aec59433b8a97df0159136cd

[28] M. Petrak, J. Carpenter. FELINE TOXOPLASMOSIS. Journal of the American Veterinary Medical Association, 1965. https://www.semanticscholar.org/paper/b716bfc934da864c863f7e5d8c3624e2dcc7c73e

[29] J. Dubey. Feline toxoplasmosis and its nematode transmission. 1968. https://www.semanticscholar.org/paper/9739e9c0ebc5b4da8a73d718ce795f65831c9bd1

[30] S. P. Pakes, W. Lai. Carbon immunoassay-a simple and rapid serodiagnostic test for feline toxoplasmosis. Laboratory Animal Science, 1985. https://www.semanticscholar.org/paper/080360020a814df09eb4c1d8667765bf1f9c6448

[31] T. Sivkova, A. Shchukina. [The epizootology of feline toxoplasmosis in the town of Perm]. Meditsinskaia Parazitologiia i Parazitarnye Bolezni, 2008. https://www.semanticscholar.org/paper/676184d88f61d78d65e2295dde6078cb8874f7e8

[32] T. Hagiwara, Y. Katsube, T. Muto et al. Experimental feline toxoplasmosis. Nihon Juigaku Zasshi, 1981. https://www.semanticscholar.org/paper/4a9f71a86da7f23dbac805ed17582f5d491c5498

[33] K. Mizusawa, K. Oosawa, K. Thoyama et al. Seroepidemiological Survey on Feline Toxoplasmosis in Saitama Prefecture. 1991. https://www.semanticscholar.org/paper/c614f887ae21d3ca12a82fdee2f1537273f48508

[34] C. Powell. Chapter 32 – Feline Toxoplasmosis. 2002. https://www.semanticscholar.org/paper/eeaf74641a89450463fddf81566a6d161f7bf133

[35] James G. Fox. Feline Toxoplasmosis, Credit for Abstract. Journal of the American Veterinary Medical Association, 1975. https://www.semanticscholar.org/paper/382bf363ea23c527950e0ba6a2b95e60bae9dbf6